Cambridge, UK, May 2021: o2h Ventures are active investors in early stage biotech therapeutics & AI. We are pleased today to share the news that Arecor, a Cambridge, UK, based biotechnology company (‘Pre-Fund Investment’ portfolio company) has had it’s U.S. Utility Patent No. 10,925,965 B2 granted by the United States Patent and Trademark Office.  This patent contributes to the Company’s global patent portfolio, underpinning its ArestatTM technology platform. The patent claims proprietary formulation technology aimed at enabling stabilised multi-dose protein products, a desirable attribute which is challenging to achieve. The US is the key international market for biopharmaceuticals and one where Arecor has already established a number of key commercial and development partnerships.